|
|
Article: Allergan Enters Into Agreement with GlaxoSmithKline to Accelerate BOTOX(R) Development and Commercialization in Japan and China, Co-Promote IMITREX STATdose System(R) and AMERGE(R) in U.S.
- Article from:
- Business Wire
- Article date:
- October 3, 2005
CopyrightCOPYRIGHT 2005 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
IRVINE, Calif. -- Allergan, Inc. (NYSE:AGN) announced today that it has entered into a long-term agreement with GlaxoSmithKline (NYSE:GSK) to develop and promote Allergan's BOTOX(R) (botulinum toxin type A) in Japan and China and to co-promote GSK's products IMITREX STATdose System(R) (sumatriptan succinate) and AMERGE(R) (naratriptan hydrochloride) in the United States.
Under the terms of the agreement, Allergan will license to GSK all clinical development and commercial rights to BOTOX(R) in Japan and China, markets in which GSK has extensive commercial, regulatory and R&D resources, as well as expertise in neurology. Allergan believes that these additional ...